AER experiment gets OMB approval
This article was originally published in The Tan Sheet
Executive Summary
A proposed experiment by FDA's Center for Drug Evaluation and Research designed to identify statements that most effectively convey OTC and Rx AER data to consumers has been approved by the Office of Management and Budget under the Paperwork Reduction Act of 1995, FDA announces. The agency proposed the experiment, "Toll-Free Number for Consumer Reporting of Drug Product Side Effects: Comprehension" following a proposed rule in 2004 requiring all OTCs approved under an NDA or ANDA to add a toll-free number and other statement to product labeling for AER purposes (1"The Tan Sheet" April 26, 2004, p. 14)...
You may also be interested in...
Toll-Free AER Number For Sec. 505 OTCs To Be On Labels One Year After Rule
FDA is planning to allow OTCs approved under an NDA or ANDA up to one year to add a toll-free number to labeling for adverse event reports, according to a 1proposed rule published in the April 22 Federal Register
US Q1 Consumer Health Earnings Preview: Label This One Historic And Challenging But Promising
US OTC drug and supplement firms’ reports of results for the first three months of 2024 began on April 19 with P&G. JP Morgan analysts say while “some retailers in the US in particular” are reducing consumer health inventories, for the overall sector they expect “a healthier balance of positive volume and lower pricing contribution.”
Keeping Track: Cancer Approvals From Lumisight Imaging To Adjuvant Alecensa
The US FDA’s approval of Lumicell’s optical imaging agent Lumisight makes a dozen novel approvals in 2024 for the Center for Drug Evaluation and Research.